Advertisement
Advertisement
U.S. markets close in 6 hours 17 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Surface Oncology, Inc. (SURF)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.1000+0.0100 (+0.92%)
As of 09:38AM EDT. Market open.
Advertisement

Surface Oncology, Inc.

50 Hampshire Street
8th Floor
Cambridge, MA 02139
United States
617 714 4096
https://www.surfaceoncology.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees67

Key Executives

NameTitlePayExercisedYear Born
Dr. Robert W. Ross M.D.Pres, CEO & Director813.01kN/A1974
Dr. Vito J. Palombella Ph.D.Chief Scientific Officer633.25kN/A1963
Dr. Alison O'Neill M.D.Chief Medical Officer649.67kN/A1961
Ms. Jessica Fees CPACFO & TreasurerN/AN/A1971
Ms. Theresa R. Boni J.D.Gen. Counsel, Sec. & Sr. VP of LegalN/AN/A1968
Ms. Lisa McGrathChief People OfficerN/AN/AN/A
Mr. Henry C. RathChief Bus. OfficerN/AN/A1971
Ms. Shannon Rourke DevensSr. VP of Devel. OperationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Surface Oncology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement